Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020.
Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020.
复制标题
DOI：
10.2471/blt.16.178475
复制
发表时间：
2017-09-01
影响因子：
11.1
通讯作者：
Walker D
中科院分区：
文献类型：
--
作者：
Ozawa S;Clark S;Portnoy A;Grewal S;Stack ML;Sinha A;Mirelman A;Franklin H;Friberg IK;Tam Y;Walker N;Clark A;Ferrari M;Suraratdecha C;Sweet S;Goldie SJ;Garske T;Li M;Hansen PM;Johnson HL;Walker D
为了估计2001年至2020年期间在73个主要由疫苗联盟支持的低收入和中等收入国家接种10种疫苗可预防的疾病的努力可能产生的经济影响。我们使用健康影响模型来估计实现对b型流感嗜血杆菌、乙肝、人乳头瘤病毒、乙型脑炎、麻疹、A组脑膜炎奈瑟菌、轮状病毒、风疹、肺炎链球菌和黄热病疫苗接种的预测覆盖范围的经济影响。与不接种疫苗相比，我们模拟了避免治疗的成本、交通成本、照顾者的生产力损失以及因残疾和死亡而造成的生产力损失的成本--以2010年美元(美元)表示。我们使用一年生命价值的方法来估计由于接种疫苗而活得更长、更健康的更广泛的经济和社会价值。我们估计，在这73个国家中，在2001年至2020年期间接种疫苗将避免2000多万人死亡，并为 节省3500亿美元的疾病成本。在这二十年中，通过接种疫苗预防的死亡和残疾将分别带来估计的终生生产力收益，总额分别为3300亿美元和90亿美元 。在接种疫苗的队列的生命周期内，相同的疫苗接种将节省约50亿美元的 治疗费用。这些疫苗的更广泛的经济和社会价值估计为8,200亿美元 。通过在世界上一些最贫穷的国家中防止巨大的成本和潜在地提高经济生产力，免疫接种的影响远远超出了健康。
To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In comparison with no vaccination, we modelled the costs – expressed in 2010 United States dollars (US$) – of averted treatment, transportation costs, productivity losses of caregivers and productivity losses due to disability and death. We used the value-of-a-life-year method to estimate the broader economic and social value of living longer, in better health, as a result of immunization. We estimated that, in the 73 countries, vaccinations given between 2001 and 2020 will avert over 20 million deaths and save US$ 350 billion in cost of illness. The deaths and disability prevented by vaccinations given during the two decades will result in estimated lifelong productivity gains totalling US$ 330 billion and US$ 9 billion, respectively. Over the lifetimes of the vaccinated cohorts, the same vaccinations will save an estimated US$ 5 billion in treatment costs. The broader economic and social value of these vaccinations is estimated at US$ 820 billion. By preventing significant costs and potentially increasing economic productivity among some of the world’s poorest countries, the impact of immunization goes well beyond health.